Epalrestat is an aldose reductase inhibitor that has been used in the clinical treatment of diabetic peripheral neuropathy for many years. By inhibiting the accumulation of sorbitol in nerves, it can effectively improve neurological symptoms and functional abnormalities in diabetic patients. For the rational use of this drug, especially when formulating individualized treatment plans, it is essential to accurately master its dosage and administration, and flexibly adjust them according to the specific conditions of patients.
Dosage and Administration of Epalrestat
Standard Dosage for Adults
The standard adult dosage of Epalrestat is 50 mg per dose (i.e., one 50 mg tablet), three times a day, with a total daily dose of 150 mg.
To ensure good absorption of the drug and optimal efficacy, it is recommended to take it orally before three daily meals (breakfast, lunch, and dinner).
Course of Treatment and Efficacy Evaluation
After the start of treatment, close observation of the patient's condition is required.
According to the instructions, if no significant improvement in clinical symptoms (such as numbness, pain, etc.) is observed after 12 consecutive weeks of medication, the doctor should re-evaluate the condition and consider switching to another more appropriate treatment plan.
Medication for Special Populations of Epalrestat
Patients with Hepatic Impairment
Epalrestat may cause hepatic dysfunction, and there is even a risk of serious side effects such as severe hepatitis and liver failure.
For patients with pre-existing liver diseases or hepatic impairment, doctors will be very cautious when prescribing this drug.
During the medication period, regular monitoring of liver function indicators (such as AST, ALT, γ-GTP, bilirubin, etc.) is crucial.
Once abnormalities occur, the drug should be discontinued immediately and corresponding treatment measures should be taken.
Patients with Renal Impairment
The instructions indicate that this product may cause increases in blood urea nitrogen and creatinine.
Although no direct dosage adjustment recommendations for patients with renal impairment are clearly given, for patients with decreased renal function, monitoring of renal function-related indicators should be strengthened during medication to alert against possible adverse reactions.
Pregnant and Lactating Women
Pregnant women: The safety of Epalrestat in pregnant women has not been fully established. It can only be considered for use when the therapeutic benefit to the mother is judged to outweigh the potential risk to the fetus.
Lactating women: Animal experiments have shown that Epalrestat can be excreted in breast milk, but whether it enters human milk is unclear. If lactating women need to take the drug, they should comprehensively consider the necessity of drug treatment and the benefits of breastfeeding, and make a careful decision on whether to continue breastfeeding or stop breastfeeding.
Children and Elderly Patients
Children: Currently, there is a lack of clinical trial data for the pediatric population, and its efficacy has not been confirmed. The use of Epalrestat in children is not recommended.
Elderly patients: The physiological functions of elderly patients are somewhat declined, and they often have other concurrent diseases. When using this product, attention should be paid to observation, and the dosage should be considered as appropriate according to their physical conditions to ensure medication safety.
